ScreenerHero

LGVNLongeveron Inc.

NAS · US · Healthcare · Biotechnology · longeveron.com
0.8449USD+2.75%Mkt Cap: 26.94M $P/E: —

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogenei…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap26.94M $
Enterprise Value16.91M $
Revenue (TTM)1.19M $
Gross Profit803.00K $
Net Income (TTM)-22.70M $
Revenue/Share0.0490 USD
Last Price0.8449 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.54
PEG—
EV/EBITDA-0.75
EV/Revenue14.24
P/S22.24
P/B1.59
EPS (TTM)-1.01
EPS (Forward)-1.53
52W Range
0.475049% of range1.230
52W High1.230 USD
52W Low0.4750 USD
Profitability
Gross Margin66.97%
Oper. Margin-2150.17%
EBITDA Margin0.00%
Profit Margin-1893.58%
ROE-400.07%
ROA-221.26%
Growth
Revenue Growth-9.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.64M $
CapEx (TTM)595.00K $
FCF Margin-977.54%
FCF Yield-43.08%
Net Debt-9.50M $
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.15
Current Ratio2.63
Quick Ratio2.35
Book Value/Sh0.5210 USD
Cash/Share0.3160 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 27, 2024
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.150 USD
Upside (mean)+746.3%
Target Range3.000 USD – 10.45 USD
$3.000+746.3% to mean$10.45
# Analysts3
Ownership
Shares Out.30.43M
Float27.03M
Insiders9.57%
Institutions19.89%
Short Interest
Short Ratio5.7d
Short % Float5.34%
Short % Out.4.92%
Shares Short1.55M
Short (prev mo.)1.59M
Technical
SMA 500.7076 (+19.4%)
SMA 2000.7218 (+17.1%)
Beta-0.25
S&P 52W Chg18.16%
Avg Vol (30d)385.87K
Avg Vol (10d)706.87K
Technical Indicators
RSI (14)65.3
MACD0.0334
MACD Signal0.0171
MACD Hist.+0.0162
BB Upper0.8666 USD
BB Middle0.7116 USD
BB Lower0.5566 USD
BB Width43.56%
ATR (14)0.0649 USD
Vol Ratio (20d)1.68x